Biotech IPOs can feel like rocket fuel—until patent due diligence turns out to be the handbrake.
If you’re an investor, operator, or advisor watching a promising pipeline approach the public markets, here’s the uncomfortable truth: the biggest value in…

Most biosimilar models fail for the same reason: they assume the market will behave like a spreadsheet.
That’s the uncomfortable takeaway from a recent DrugPatentWatch piece on the costly mistakes companies make when modeling biosimilar entry windows…

Most teams don’t fail at “strategy.” They fail at the moment they decide.
In generic and biosimilar development, the hardest part isn’t the science—it’s the go/no-go decision that comes before the science is fully de-risked. And that’s where many progr…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the real fight often isn’t the active ingredient—it’s the moat built around it.
For years, the industry has focused on the headlin…

Pharma doesn’t just “own” patents—it engineers time.
In a world where blockbuster drugs face relentless pressure from generics, the real competitive advantage often isn’t the original patent grant. It’s what comes after: patent term extensions, seconda…

Your pharmaceutical portfolio has a time bomb in it. Patent expiration data tells you where.
If you’re leading strategy, BD, or portfolio management in pharma, you already know the uncomfortable truth: the next “big” launch is rarely the biggest risk. …

The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/

Big Pharma loves a good wall.
Not the kind you can scale with grit and a ladder—but the kind built from patents, procedural delays, and “trust us” narratives. In the pharmaceutical world, IP strategy can feel like a fortress: opaque, expensive to chall…

Brands Don’t Launch “Competition” by Accident—They Do It to Control the Next Phase of the Market
There’s a quiet strategy playing out across pharma that most investors only notice after the damage is done: the authorized generic.
On the surface, it loo…

Dairy-Free Alternatives to Lipitor: Exploring Options for Statin-Free Heart Health As the world becomes increasingly aware… https://www.Drugchatter.com/chat/1561/are-there-any-dairy-free-alternatives-to-lipitor/